Navigation Links
VOICE study will continue as it considers what action to take after results of 2 trials
Date:7/13/2011

PITTSBURGH, July 13, 2011 Today, researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP. One of these trials, the Partners PrEP Study, has provided the strongest evidence yet of PrEP's effectiveness.

Information from both studies will need to be fully evaluated before it can be determined what impact they will have on another major trial that is ongoing. Investigators for VOICE Vaginal and Oral Interventions to Control the Epidemic, and the study's sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), hope to complete their evaluation as soon as possible. In the meantime, the five-arm study involving more than 5,000 women in sub-Saharan Africa will continue as currently designed.

PrEP involves the use of antiretroviral (ARV) drugs commonly used in the treatment of HIV by individuals who are not infected. In the Partners PrEP Study, researchers from the University of Washington and their collaborators in Uganda and Kenya, evaluated the safety and effectiveness of daily use of two ARVs tenofovir and Truvada, the brand name for a tablet combining tenofovir and emtricitabine among men and women in a discordant relationship with a partner who is HIV-positive. The study enrolled 4,758 serodiscordant couples.

There were 62 percent fewer HIV infections among participants assigned to take the ARV tenofovir daily compared to participants who took a placebo tablet, and 73 percent fewer infections among those who took Truvada. In statistical terms, the results leave little doubt they are not due to chance. However, the study was not able to say whether Truvada or tenofovir works better than the other in preventing HIV.

The results came to light during a review conducted by Partner PrEP's independent Data Safety and Monitoring Board (DSMB) just a few days ago, on July 10. T
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-916-3315
Microbicide Trials Network
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Three NHS Trusts Choose BigHand Voice Technology Under YHCPC Framework Agreement
2. The Voice of Compassionate Cancer Treatment Just Got Louder: Website Provides Resources and a Call to Action for the Medical Community
3. Employers Voice Opinions on Health Care Plans, Gain Insights on Health Care Reform
4. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction
5. Independent Womens Voice Releases Health Care Poll
6. VoiceNation Helps Non-Profits Gather Funding for Those in Need
7. Infants Sensitivity to Voices May Develop by 7 Months
8. The Scarlet I: Infertility survivors lend voices to U of I profs new book
9. Voice Analysis May Allow Early Detection of Parkinsons
10. More than 60 percent of teachers have voice problems
11. Now Hiring: VoipWalker, Inc. DBA VoiceWalker, Experiences Significant Up-Tick in Business, Enters Hiring Mode
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... the World; First Centers to Open ... France and China, Kenneth P. Moritsugu, M.D., Former Acting Surgeon General, Appointed to ... Lead Global ... today announced the establishment of the Johnson &,Johnson Diabetes Institute (JJDI) to transform diabetes ...
... IT Services Leader Will Provide Systems Operations, ... Military Health System Computing Environment, ARLINGTON, ... leading global,provider of information management and business ... awarded the Military Health System,Executive Information and ...
... MedPredict Market Research,a global provider of pharmaceutical ... report providing critical strategic insight,for pharma and biotech ... anxiety and,depression therapies. In this report, entitled ... physician experts from North America and Europe,discuss the ...
... and Oncology is pleased to announce that Stefanie LaRue of ... Circle Award winner. Ms. LaRue will be presented with her ... 2007, at 8:00 a.m. at the Los Angeles Convention Center ... 28 through November 1 in Los Angeles., The Survivor Circle ...
... existing regimen may help, researchers say , TUESDAY, Oct. ... as an added therapy, the epilepsy drug lamotrigine is ... , The 239 participants, aged 13 and older, were ... They were already taking one or two medications, but ...
... For the seventh,consecutive year West Coast Bank will partner ... the Heart of Doernbecher Auction, which,has raised over $2.5 ... tie event will be held at Portland Art Museum, ... Bank,s Executive Vice President of Commercial Banking Xandra,McKeown serves ...
Cached Medicine News:Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 4Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies 2Health News:LA breast cancer activist honored with Survivor Circle Award 2Health News:LA breast cancer activist honored with Survivor Circle Award 3Health News:Lamotrigine May Reduce Epilepsy Seizures 2Health News:West Coast Bank Will Sponsor the Heart of Doernbecher Auction at the Portland Art Museum, October 20, 2007 2
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: